IRIS
PREVITI, Santo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 3.287
NA - Nord America 2.226
AS - Asia 1.560
SA - Sud America 487
Continente sconosciuto - Info sul continente non disponibili 331
AF - Africa 51
OC - Oceania 4
Totale 7.946
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.153
RU - Federazione Russa 1.767
SG - Singapore 638
IT - Italia 430
BR - Brasile 409
CN - Cina 408
IE - Irlanda 300
HK - Hong Kong 216
SE - Svezia 180
PL - Polonia 178
VN - Vietnam 111
FR - Francia 109
DE - Germania 81
AT - Austria 71
GB - Regno Unito 53
IN - India 37
MX - Messico 36
BE - Belgio 32
AR - Argentina 27
CA - Canada 23
FI - Finlandia 23
IQ - Iraq 23
BD - Bangladesh 22
NL - Olanda 19
MA - Marocco 15
ID - Indonesia 14
TR - Turchia 14
CO - Colombia 13
UZ - Uzbekistan 12
PK - Pakistan 11
ZA - Sudafrica 11
EC - Ecuador 10
UA - Ucraina 9
ES - Italia 8
VE - Venezuela 8
PY - Paraguay 7
JP - Giappone 6
MY - Malesia 6
AE - Emirati Arabi Uniti 5
CL - Cile 5
DZ - Algeria 5
LT - Lituania 5
SA - Arabia Saudita 5
TN - Tunisia 5
AZ - Azerbaigian 4
CR - Costa Rica 4
CZ - Repubblica Ceca 4
KE - Kenya 4
PE - Perù 4
AU - Australia 3
GE - Georgia 3
JM - Giamaica 3
KR - Corea 3
KW - Kuwait 3
LB - Libano 3
PH - Filippine 3
UY - Uruguay 3
BA - Bosnia-Erzegovina 2
BG - Bulgaria 2
CH - Svizzera 2
CI - Costa d'Avorio 2
EG - Egitto 2
GR - Grecia 2
IR - Iran 2
JO - Giordania 2
KG - Kirghizistan 2
KZ - Kazakistan 2
LV - Lettonia 2
MD - Moldavia 2
NI - Nicaragua 2
PR - Porto Rico 2
RS - Serbia 2
SY - Repubblica araba siriana 2
AL - Albania 1
BO - Bolivia 1
BY - Bielorussia 1
DO - Repubblica Dominicana 1
ET - Etiopia 1
GA - Gabon 1
HN - Honduras 1
IL - Israele 1
LY - Libia 1
MK - Macedonia 1
ML - Mali 1
MM - Myanmar 1
MN - Mongolia 1
MU - Mauritius 1
NZ - Nuova Zelanda 1
RO - Romania 1
SN - Senegal 1
SV - El Salvador 1
TZ - Tanzania 1
Totale 7.615
Salva come PNG Salva come JPEG
Città #
Moscow 538
Singapore 354
Ashburn 342
Dublin 300
Chandler 251
Hong Kong 216
Warsaw 176
Messina 161
Nyköping 148
Beijing 128
Dallas 122
San Jose 112
Council Bluffs 96
Vienna 62
Princeton 50
Los Angeles 45
Ann Arbor 38
Lauterbourg 38
The Dalles 38
Ho Chi Minh City 35
Medford 34
Redondo Beach 33
Des Moines 31
Santa Clara 31
São Paulo 26
Guangzhou 24
Hanoi 24
New York 23
Frankfurt am Main 21
Brussels 20
Aversa 19
Jacksonville 19
Rome 18
Brasília 16
Dearborn 16
Montpellier 16
Munich 16
Orem 16
Houston 15
Cambridge 14
Mexico City 14
Modica 14
Buffalo 13
San Mateo 13
Montreal 12
Tashkent 12
Tianjin 12
Amsterdam 11
Baghdad 11
Belo Horizonte 10
Catania 10
Chennai 10
Rio de Janeiro 10
San Francisco 10
Shenzhen 10
Bari 9
Boston 9
Curitiba 9
Denver 9
Jinan 9
London 9
Atlanta 8
Brooklyn 8
Chicago 8
Ixelles-Elsene 8
Phoenix 8
Stockholm 8
Bexley 7
Helsinki 7
Milan 7
Siderno 7
Wilmington 7
Berlin 6
Campinas 6
Columbus 6
Francavilla di Sicilia 6
Goiânia 6
Haikou 6
Medellín 6
Nuremberg 6
Querétaro 6
Shanghai 6
Shenyang 6
Taizhou 6
Tokyo 6
Biên Hòa 5
Boardman 5
Francofonte 5
Istanbul 5
Johannesburg 5
Manchester 5
Poplar 5
Porto Alegre 5
Portsmouth 5
Riposto 5
Seattle 5
Southampton 5
Ankara 4
Borghetto Santo Spirito 4
Brno 4
Totale 4.141
Salva come PNG Salva come JPEG
Nome #
Design, synthesis and biological evaluation of novel inhibitors of rhodesain, cysteine protease of Trypanosoma brucei rhodesiense, as antitrypanosomal agents 347
Development of novel Michael acceptors targeting rhodesain as antitrypanosomal agents 207
Design, synthesis and biological evaluation of novel rhodesain inhibitors for the treatment of Human African Trypanosomiasis 192
Identification of 2-thioxoimidazolidin-4-one derivatives as novel noncovalent proteasome and immunoproteasome inhibitors 189
Design, synthesis and biological evaluation of novel dipeptide-like rhodesain inhibitors containing a conformationally constrained 3-bromoisoxazoline warhead 169
Development of novel 1,4-benzodiazepine-based Michael acceptors as antitrypanosomal agents 163
Design and NMR conformational analysis in solution of β5i-selective inhibitors of immunoproteasome 162
Synthesis and biological evaluation of novel peptidomimetics as rhodesain inhibitors 161
Development of Urea-Bond-Containing Michael Acceptors as Antitrypanosomal Agents Targeting Rhodesain 157
Development of novel amides as non covalent inhibitors of immunoproteasome 155
Development of novel irreversible rhodesain inhibitors as antitrypanosomal agents. 154
Development of novel dipeptide nitriles as inhibitors of rhodesain of Trypanosoma brucei rhodesiense 154
Development of novel benzodiazepine-based peptidomimetics as inhibitors of rhodesain of Trypanosoma brucei rhodesiense 149
Design and evaluation of non-carboxylate 5-arylidene-2-thioxo-4-imidazolidinones as novel non-competitive inhibitors of protein tyrosine phosphatase 1B 149
Evaluation of curcumin irreversibility 148
Drug combination studies of isoquinolinone AM12 with curcumin or quercetin: a new combination strategy to synergistically inhibit 20S proteasome 146
Drug combination studies of curcumin and genistein against rhodesain of Trypanosoma brucei rhodesiense 145
Discovery of novel peptidomimetics containing a benzodiazepine scaffold as inhibitors of rhodesain of Trypanosoma brucei rhodesiense 142
Development of novel 1,4-benzodiazepines as antitrypanosomal agents 141
Immunoproteasome-selective inhibitors: a promising strategy to treat hematologic malignancies, autoimmune and inflammatory diseases 139
Development of novel dipeptide nitriles as inhibitors of rhodesain of Trypanosoma brucei hodesiense 138
Development of isoquinolinone derivatives as immunoproteasome inhibitors. 134
Optimization Strategy of Novel Peptide-Based Michael Acceptors for the Treatment of Human African Trypanosomiasis 133
Design, synthesis and biological evaluation of potent rhodesain inhibitors as antitrypanosomal agents 131
Development of Novel Benzodiazepine-Based Peptidomimetics as Inhibitors of Rhodesain from Trypanosoma brucei rhodesiense 126
A second opportunity for the peptide-based analogues with γ-lactam at the P1 position: human cathepsin S inhibition 125
Structure-based lead optimization of peptide-based vinyl methyl ketones as SARS-CoV-2 main protease inhibitors 124
The Inhibition of Cysteine Proteases Rhodesain and TbCatB: A Valuable Approach to Treat Human African Trypanosomiasis 122
Development of Novel Peptide-based Michael Acceptors Targeting Rhodesain and Falcipain-2 for the Treatment of Neglected Tropical Diseases (NTDs) 122
Development of novel dipeptide-like rhodesain inhibitors containing the 3-bromoisoxazoline warhead in a constrained conformation 122
Development of novel peptidyl nitriles targeting rhodesain and falcipain-2 for the treatment of sleeping sickness and malaria 119
Development of peptidyl Michael acceptors for S3 pocket investigation of rhodesain, cysteine protease of Trypanosoma brucei rhodesiense 118
Dipeptide nitrile CD34 with curcumin: a new improved combination strategy to synergistically inhibit rhodesain of Trypanosoma brucei rhodesiense 118
Monoclonal antibodies: the greatest resource to treat multiple myeloma 116
Development of reduced peptide bond pseudopeptide Michael acceptors for the treatment of Human African Trypanosomiasis 115
Structure-based lead optimization of peptide-based vinyl methyl ketones as SARS-CoV-2 main protease inhibitors 114
Development of novel peptide-based Michael acceptors targeting rhodesain and falcipain-2 for the treatment of neglected tropical diseases (NTDs) 114
Peptidyl Vinyl Ketone Irreversible Inhibitors of Rhodesain: Modifications of the P2 Fragment 105
Drug synergism: studies of combination of RK-52 and curcumin against rhodesain of Trypanosoma brucei rhodesiense 98
Neurotensin, a multi-faceted peptide 98
Drug combination studies of the dipeptide nitrile CD24 with curcumin: a new strategy to synergistically inhibit rhodesain of trypanosoma brucei rhodesiense 95
Lead discovery of SARS-CoV-2 main protease inhibitors through covalent docking-based virtual screening 95
Falcipain-2 and Falcipain-3 inhibitors as promising antimalarial agents 95
Drug combination studies of PS-1 and quercetin against rhodesain of Trypanosoma brucei rhodesiense 95
Development of novel peptide-based Michael acceptors targeting rhodesain for the treatment of human african trypanosomiasis 92
Optimization of radiopharmaceuticals based on neurotensin[8-13] for NTS1-positive tumours imaging 91
Silicon-containing neurotensin analogues as radiopharmaceuticals for NTS1-positive tumors imaging 90
Design, synthesis, and in vitro characterization of proteolytically-stable opioid-neurotensin hybrid peptidomimetics 88
CAR-T cell therapy for prostate cancer: current advances and future perspectives 88
Identification of dual inhibitors targeting main protease (Mpro) and cathepsin L as potential anti-SARS-CoV‑2 agents 85
Optimized opioid-neurotensin multitarget peptides: from design to structure−activity relationship studies 84
Structure-based design of melanocortin 4 receptor ligands based on the SHU-9119-hMC4R cocrystal structure 84
Design and synthesis of opioid-neurotensin hybrid peptidomimetics: analgesics with reduced side effect profiles 83
Identification of constrained peptidomimetics carrying a Michael acceptor warhead as antitrypanosomal agents 79
Design, synthesis, and biological evaluation of the first radio-metalated neurotensin analogue targeting neurotensin receptor 2 78
The inhibition of NS2B/NS3 protease: a new therapeutic opportunity to treat Dengue and Zika virus infection 73
Design and synthesis of 68Ga-labeled peptide-based heterodimers for dual targeting of NTS1 and GRPR 70
Development of peptide-based SARS CoV-2 Mpro/hCatL dual inhibitors as antiviral agents 68
Dual inhibition of parasitic targets: a valuable strategy to treat malaria and neglected tropical diseases 65
Synthesis and Combination Studies of Novel Dipeptide Nitriles with Curcumin for a Potent Synergistic Action Against Rhodesain, Cysteine Protease of Trypanosoma brucei rhodesiense 58
The role of nutraceuticals in chemoprevention and their therapeutic effects when used in combination with synthetic drugs 53
Insightful backbone modifications preventing proteolytic degradation of neurotensin analogs improve NTS1-induced protective hypothermia 53
null 50
The Role of Nutraceuticals in Age-Related Ocular Diseases 44
Metabolically stable neurotensin analogs exert potent and long-acting analgesia without hypothermia 39
Selected Nutraceuticals in Metabolic Syndrome: Molecular Mechanisms and Clinical Implications 30
Opening the amino acid toolbox for peptide-based NTS2-selective ligands as promising lead compounds for pain management 28
null 28
Influence of amino acid size at the P3 position of N-Cbz-tripeptide Michael acceptors targeting falcipain-2 and rhodesain for the treatment of malaria and human african trypanosomiasis 27
Hybrid synthetic approach and biological characterization of a branched heterodimer for overcoming prostate cancer heterogeneity 26
Rational design of NT-PSMA heterobivalent probes for prostate cancer theranostics 23
null 22
null 22
N-Terminal stabilization of radiolabeled neurotensin analogues for improved tumor uptake 20
Supplement: 37th European Peptide Symposium 14th International Peptide Symposium August 25–August 29, 2024 | Florence, Italy 17
Development of Novel Proline- and Pipecolic Acid-Based Allosteric Inhibitors of Dengue and Zika Virus NS2B/NS3 Protease 16
Inhibitors of proteases: a well-grounded strategy in drug development 15
Macrocycles and stapled-peptides in the fight against SARS-CoV-2: a review 11
Synthesis of New Asymmetrical Chalcones and Evaluation of Their Use in Combination with Curcumin Against Rhodesain of T. brucei rhodesiense 5
Totale 7.946
Salva come PNG Salva come JPEG
Categoria #
all - tutte 25.240
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 25.240
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022289 0 30 3 23 9 7 44 8 3 20 20 122
2022/2023981 62 94 42 77 55 103 47 78 364 4 48 7
2023/2024319 43 47 18 60 45 11 7 6 2 29 33 18
2024/20251.182 30 9 23 94 41 22 76 195 272 80 129 211
2025/20264.051 162 209 231 290 336 846 547 497 530 215 70 118
2026/2027327 90 237 0 0 0 0 0 0 0 0 0 0
Totale 7.946